AliveDx Suisse S.A. and Sedeer Medical Services and Trading Co. LLC have signed a distribution agreement, which will enable Sedeer to distribute the MosaiQ® and LumiQ™ solutions in Qatar. The distribution agreement takes effect immediately.
AliveDx is committed to expanding its global presence and advancing autoimmune diagnostics. Through strategic collaborations, such as this partnership in Qatar, we strengthen our dedication to supporting the healthcare sector and improving patient care. Our groundbreaking solutions simplify laboratory workflows, delivering both clinical and economic value while helping clinicians shorten the time to diagnosis.
The combination of the MosaiQ and LumiQ platforms simplifies workflows and enhances efficiency through advanced multiplexing microarray assay technology. This streamlined approach delivers faster, more cost-effective solutions, benefiting both healthcare providers and patients.
“Our partnership with Sedeer reinforces our commitment to advancing patient care on a global scale. We are excited to collaborate with them and support the growth and innovation of Qatar’s healthcare system,” said Manuel O. Méndez, CEO of AliveDx.
Sedeer was established in 2001. The company is a total solution provider and distributor in various sectors, such as healthcare, research, forensics, veterinary, diagnostics, and life sciences among others. Their mission is to provide premium quality services for a healthier, safer and cleaner world.
“We are honored to collaborate with AliveDx. As part of our group’s initiatives to expand our diagnostic business portfolio, incorporating AliveDx’s solutions marks a significant step into the immunology diagnostics segment. We believe the MosaiQ and LumiQ solutions will empower us to provide Qatar’s healthcare sector with the latest, best-in-class technologies that will positively impact patient care,” said Shanavas Thekkoth General Manager of Sedeer Medical Services and Trading Co. LLC.
To learn more, please visit the Seeder website.
